Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 13/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.77 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.77 |
| ▸ | HTR2C | P28335 | 2/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.77 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018017 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL30734435 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL27075590 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL10380334 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL19464266 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| SCHEMBL7447363 | 1.00 | DRD1 (1.00) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL31018036 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877853 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877854 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL1877856 | 0.99 | DRD1 (0.97) | DRD1KDM4ETP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | claimed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | claimed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | claimed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | disclosed |
| US-20210038561-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2019152733-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20160317474-A1 | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects | UNIV EMORY (US) | 2016-11-03 | — | — | US | disclosed |
| WO-2015095257-A2 | MANAGING VISUAL DYSFUNCTION OR LOSS OF VISION FOR DIABETIC SUBJECTS | EMORY UNIVERSITY (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-1689704-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | CoLucid Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005042475-A2 | CARBAMOYL ESTERS THAT INHIBIT CHOLINESTERASE AND RELEASE PHARMACOLOGICALLY ACTIVE AGENTS | SENTION, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| WO-1996038435-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038561-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885KDM4E 3556/4885TP53 4088/4885 |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | ACHE, BCHE, CHAT | DRD1 2365/4885KDM4E 136/4885TP53 3959/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD1 4882/4885KDM4E 3556/4885TP53 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.